Virios Therapeutics CEO Highlights Novel Therapeutic Approach for Treating Fibromyalgia and Irritable Bowel Syndrome in Stock News Now Video Interview

Rhea-AI Summary

Virios Therapeutics (Nasdaq: VIRI) announced significant updates regarding its antiviral development strategies during a video interview with Stock News Now. CEO Greg Duncan discussed the ongoing Phase 2b trial for the company's lead candidate, IMC-1, which is targeting fibromyalgia. IMC-1, a combination of famciclovir and celecoxib, aims to suppress HSV-1 replication, with promising results from a previous Phase 2a trial. The company plans to expand its pipeline to include treatments for irritable bowel syndrome and fatigue-related disorders.

Positive

• Ongoing Phase 2b trial for IMC-1 to treat fibromyalgia.
• Previous Phase 2a trial demonstrated efficacy of IMC-1.
• IMC-1 received fast track designation from the FDA.
• Plans to expand pipeline to include IBS and fatigue-related disorders.

Negative

• Risks and uncertainties associated with the completion and timing of the Phase 2b trial.

Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, announced today that Chairman and CEO, Greg Duncan, highlighted the Company’s novel combination antiviral development approach, its ongoing Phase 2b trial Fibromyalgia trial and plans for expanded pipeline programs in irritable bowel syndrome (IBS) and fatigue related disorders during a video interview with Stock News Now, a microcap financial news portal that features news and insights from the microcap and emerging growth financial community.

The archived replay of the interview may be accessed on the Virios Therapeutics website under the Investors section: Events and Presentations.

About Virios Therapeutics

Virios Therapeutics (Nasdaq: VIRI) is a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, such as fibromyalgia (“FM”). Immune responses related to the activation of tissue resident Herpes Simplex Virus-1 (“HSV-1”) have been postulated as a potential root cause triggering and/or sustaining chronic illnesses such as FM, irritable bowel syndrome (“IBS”), chronic fatigue syndrome and other functional somatic syndromes, all of which are characterized by waxing and waning symptoms with no obvious etiology. Our lead development candidate (“IMC-1”) is a novel, proprietary, fixed dose combination of famciclovir and celecoxib designed to synergistically suppress HSV-1 replication, with the end goal of reducing virally promoted disease symptoms.

Evidence of IMC-1’s efficacy on a broad spectrum of FM outcome measures was previously demonstrated in a Phase 2a clinical trial. These trial results are suggestive that IMC-1 may represent a new and novel treatment for fibromyalgia. IMC-1 has been granted fast track designation by the FDA and is currently being tested in a multi-center, randomized, double-blind, placebo-controlled Phase 2b trial (“FORTRESS”) designed to set the stage for registrational studies. The company is led by an executive team highly experienced in the successful development and commercialization of novel therapies. For more information, please visit www.virios.com.

Forward-Looking Statements

Statements in this press release contain “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” "will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Virios Therapeutics’ current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the completion and timing of the Phase 2b trial. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the Annual Report on Form 10-K for the year ended December 31, 2020 filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Virios Therapeutics, Inc. (VIRI) undertakes no duty to update such information except as required under applicable law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210816005040/en/

FAQ

What is the current status of Virios Therapeutics' Phase 2b trial for IMC-1?

The Phase 2b trial for IMC-1, targeting fibromyalgia, is currently ongoing.

What is IMC-1 and its significance for Virios Therapeutics?

IMC-1 is a novel antiviral treatment combining famciclovir and celecoxib, aimed at suppressing HSV-1 replication.

What previous clinical trial results support IMC-1's efficacy?

A Phase 2a clinical trial previously demonstrated IMC-1's efficacy on a broad spectrum of fibromyalgia outcome measures.

What future plans does Virios Therapeutics have for its drug pipeline?

Virios plans to expand its pipeline to include treatments for irritable bowel syndrome and fatigue-related disorders.

What are the risks associated with Virios Therapeutics' forward-looking statements?

The company faces substantial risks and uncertainties, including those related to the completion and timing of the Phase 2b trial.